Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …

The ability to gain spatiotemporal information, and in some cases achieve spatiotemporal
control, in the context of drug delivery makes theranostic fluorescent probes an attractive …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Background Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow
cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is …

Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Background The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may
initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized …

Importance There are limited efficacious treatments for Alzheimer disease. Objective To
assess efficacy and adverse events of donanemab, an antibody designed to clear brain …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet
medical need worldwide. The pathogenesis of AD involves various pathophysiological …